Women's Health Market Projected to Hit $600B by 2030

Women’s health has become one of the defining investment themes in global healthcare. A 2026 PwC analysis projects the market will surpass $600 billion by 2030, up from $195-205 billion under traditional definitions, or $430-440 billion when fitness, nutrition, and mental wellness are included.

A gap built over decades

The growth numbers read as opportunity. But the baseline reveals a structural problem. Just 5% of global healthcare research and development spending currently targets women’s health. As Margaret Malone noted in the PwC analysis, “Women’s health has historically been boxed into reproductive care.” Contraception, pregnancy, and menstruation have defined the category for decades, leaving the decades that follow largely unaddressed.

The consequences are measurable. Cardiovascular disease presents differently in women than men, often with subtler symptoms that lead to delayed diagnosis. Autoimmune conditions (diseases where the immune system attacks the body’s own tissue, including rheumatoid arthritis and lupus) affect women at two to three times the rate they affect men. Metabolic shifts during and after menopause alter cardiovascular risk profiles significantly. Yet clinical trials have historically skewed toward male participants, and product development has followed.

Menopause leads the acceleration

The menopause segment is growing at 13% annually, well above the broader healthcare market average. Two converging forces explain it.

First, Baby Boomer women (born 1946-1964) are entering menopause at scale. In the United States alone, approximately 6,000 women reach menopause every day. The sheer demographic size of this cohort has changed the commercial calculus.

Second, the FDA removed the black box warning that had been attached to hormone replacement therapy (HRT, a treatment that supplements declining hormones) since 2002. A large clinical study that year associated HRT with elevated cardiovascular and cancer risks. More than two decades of subsequent research has refined and largely walked back those conclusions. With the warning removed, both clinician prescribing patterns and consumer interest have shifted.

Precision nutrition as the next layer

Investment is moving into precision nutrition, an approach that tailors nutritional support to an individual’s specific physiological state rather than applying population-wide averages. For women in perimenopause and menopause (the years before and after the final menstrual period), this means formulating for hormone-influenced changes in bone density, cardiovascular health, cognitive function, and metabolic rate, not just managing hot flashes.

Supplement brands, digital health platforms, and diagnostic companies are all entering the space simultaneously. The opportunity is not just in products that address immediate symptoms, but in building systems that support women across the full arc of hormonal transition.

What the $600B number represents

The projection is not simply a market growth story. It marks a shift in how the healthcare industry is defining and prioritizing women’s health. The gap between 5% of R&D and 13% annual menopause investment growth is the space where the next five years of innovation will happen. Products that would have been niche a decade ago are becoming the baseline expectation.